Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.5270
-0.0230 (-4.18%)
At close: Apr 1, 2025, 4:00 PM
0.5364
+0.0094 (1.78%)
After-hours: Apr 1, 2025, 4:22 PM EDT
Company Description
Oncolytics Biotech Inc. operates as a clinical-stage biopharmaceutical company.
The company develops pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms to improve the ability of the immune system to fight cancer, making tumors more susceptible to a range of oncology treatments.
It entered an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies.
The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc.
| Country | Canada |
| Founded | 1998 |
| IPO Date | Nov 8, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Wayne Pisano |
Contact Details
Address: 322 11th Avenue SW, Suite 804 Calgary, AB T2R 0C5 Canada | |
| Phone | 403 670 7377 |
| Website | oncolyticsbiotech.com |
Stock Details
| Ticker Symbol | ONCY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| CIK Code | 0001129928 |
| CUSIP Number | 682310875 |
| ISIN Number | CA6823108759 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wayne F. Pisano M.B.A. | Interim Chief Executive Officer and Chairman of the Board |
| Kirk J. Look C.A., CPA | Chief Financial Officer |
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Allison Hagerman P.Eng., P.M.P. | Vice President of Product Development |
| Amy Goodowitz Levin B.S.N., R.N. | Vice President of Clinical Operations |
| Jon Patton | Director of Investor Relations and Communication |
| Christophe Degois | Vice President of Business Development |
| John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 7, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 7, 2025 | 6-K | Report of foreign issuer |
| Feb 25, 2025 | 6-K | Report of foreign issuer |
| Feb 19, 2025 | 6-K | Report of foreign issuer |
| Feb 18, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | 6-K | Report of foreign issuer |
| Feb 10, 2025 | 6-K | Report of foreign issuer |
| Jan 22, 2025 | 6-K | Report of foreign issuer |
| Jan 15, 2025 | 6-K | Report of foreign issuer |